277 related articles for article (PubMed ID: 16831964)
21. Optical coherence tomography in neuromyelitis optica.
de Seze J; Blanc F; Jeanjean L; Zéphir H; Labauge P; Bouyon M; Ballonzoli L; Castelnovo G; Fleury M; Defoort S; Vermersch P; Speeg C
Arch Neurol; 2008 Jul; 65(7):920-3. PubMed ID: 18625858
[TBL] [Abstract][Full Text] [Related]
22. An open label study of the effects of rituximab in neuromyelitis optica.
Cree BA; Lamb S; Morgan K; Chen A; Waubant E; Genain C
Neurology; 2005 Apr; 64(7):1270-2. PubMed ID: 15824362
[TBL] [Abstract][Full Text] [Related]
23. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Ostberg A; Pittas F; Taylor B
Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
[TBL] [Abstract][Full Text] [Related]
24. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
[TBL] [Abstract][Full Text] [Related]
25. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.
Hamzehloo A; Etemadifar M
Arch Iran Med; 2007 Jan; 10(1):59-64. PubMed ID: 17198456
[TBL] [Abstract][Full Text] [Related]
26. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
[TBL] [Abstract][Full Text] [Related]
27. Grading cervical cord damage in neuromyelitis optica and MS by diffusion tensor MRI.
Benedetti B; Valsasina P; Judica E; Martinelli V; Ghezzi A; Capra R; Bergamaschi R; Comi G; Filippi M
Neurology; 2006 Jul; 67(1):161-3. PubMed ID: 16832101
[TBL] [Abstract][Full Text] [Related]
28. [Mitoxantrone for the treatment of patients with multiple sclerosis].
Komori M; Kondo T; Tanaka M
Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
[TBL] [Abstract][Full Text] [Related]
29. Neuromyelitis optica in Brazil: a study on clinical and prognostic factors.
Bichuetti DB; Oliveira EM; Souza NA; Rivero RL; Gabbai AA
Mult Scler; 2009 May; 15(5):613-9. PubMed ID: 19299436
[TBL] [Abstract][Full Text] [Related]
30. [Neuromyelitis optica/Devic's syndrome: new perspectives].
Lalive PH; Perrin L; Chofflon M
Rev Med Suisse; 2007 Apr; 3(106):950-5. PubMed ID: 17575971
[TBL] [Abstract][Full Text] [Related]
31. Brain involvement in neuromyelitis optica spectrum disorders.
Chan KH; Tse CT; Chung CP; Lee RL; Kwan JS; Ho PW; Ho JW
Arch Neurol; 2011 Nov; 68(11):1432-9. PubMed ID: 22084126
[TBL] [Abstract][Full Text] [Related]
32. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica.
Cabrera-Gómez JA; Quevedo-Sotolongo L; González-Quevedo A; Lima S; Real-González Y; Cristófol-Corominas M; Romero-García K; Ugarte-Sánchez C; Jordán-González J; de la Nuez JE; Lahera JG; Tellez R; Pedroso-Ibañez I; Roca RR; Cabrera-Núñez AY
Mult Scler; 2007 Mar; 13(2):186-92. PubMed ID: 17439883
[TBL] [Abstract][Full Text] [Related]
33. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
Bedi GS; Brown AD; Delgado SR; Usmani N; Lam BL; Sheremata WA
Mult Scler; 2011 Oct; 17(10):1225-30. PubMed ID: 21622594
[TBL] [Abstract][Full Text] [Related]
34. [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].
Kohriyama T; Higaki M; Matsumoto M
Nihon Rinsho; 2003 Aug; 61(8):1381-7. PubMed ID: 12962027
[TBL] [Abstract][Full Text] [Related]
35. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.
Warabi Y; Matsumoto Y; Hayashi H
J Neurol Sci; 2007 Jan; 252(1):57-61. PubMed ID: 17125797
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Le Page E; Leray E; Edan G;
Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
[TBL] [Abstract][Full Text] [Related]
37. Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse.
Milano E; Di Sapio A; Malucchi S; Capobianco M; Bottero R; Sala A; Gilli F; Bertolotto A
Neurol Sci; 2003 Oct; 24(3):130-3. PubMed ID: 14600824
[TBL] [Abstract][Full Text] [Related]
38. Neuromyelitis optica: new findings on pathogenesis.
Wingerchuk DM
Int Rev Neurobiol; 2007; 79():665-88. PubMed ID: 17531863
[TBL] [Abstract][Full Text] [Related]
39. Sjogren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of neuromyelitis optica.
Kim SM; Waters P; Vincent A; Kim SY; Kim HJ; Hong YH; Park KS; Min JH; Sung JJ; Lee KW
Mult Scler; 2009 Sep; 15(9):1062-8. PubMed ID: 19692434
[TBL] [Abstract][Full Text] [Related]
40. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system.
Argyriou AA; Makris N
Acta Neurol Scand; 2008 Oct; 118(4):209-17. PubMed ID: 18336627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
